CD Formulation's professional R&D team, with extensive experience and capabilities, utilizes ample resources, complete production equipment, and advanced facilities. As your long-term strategic partner, we aim to provide customers with high efficiency, maximize production capacity, save customers' time and costs, and deliver reliable and cost-effective nucleic acid drugs.
This includes increasing content, reducing impurities, improving appearance and color, enhancing flowability, and extending shelf life.
Including improving yield, replacing raw materials, shortening reaction cycles, and recovering solvents, among others.
Refers to the optimization of increasing production capacity under the conditions of the existing production process, including the adjustment of batch size, fine-tuning of scale-up process parameters, etc.
Refers to the optimized treatment of the three types of waste (gas, liquid, solid), including the absorption of waste gas, the recycling of waste liquid, and the utilization of waste residue.
Fig.1 Advantages of nucleic acid process design and optimization. (CD Formulation)
Every stage of drug preparation and optimization impacts your final product and raises costs. At CD Formulation, we possess the expertise to optimize each stage, guaranteeing that you achieve the desired results and attain the highest level of efficiency throughout the process.
We combine our expertise in materials and processing with the knowledge we have gained over the years by collaborating with clients from various industries on a wide range of projects to assist you in developing and optimizing your products. Our current services for nucleic acid design and optimization encompass raw material screening and optimization, reaction condition optimization, and route exploration and development for nucleic acid drugs.
Our Capabilities
Our experts work side by side with R&D and engineering teams to help bring novel or improved products to the market.
Fig.2 Flow chart of nucleic acid drugs process design and optimization. (CD Formulation)
The first step is to design a feasible synthetic route based on the structural characteristics of the target nucleic acid molecule. Factors such as reaction reagents, reaction conditions, reaction sequence, and other variables need to be considered.
In order to comprehensively assess the quality of the product, it is necessary to establish analytical methods for the physical and chemical properties of raw materials, intermediates, and final products. Techniques such as HPLC, mass spectrometry, and nuclear magnetic resonance are essential. Additionally, determining quality control indexes, including purity, impurity profiles, and content, is crucial.
After determining the synthetic route, it is necessary to evaluate the separation and purification techniques, such as chromatography, crystallization, membrane separation, etc., and select the appropriate method.
In order to transition from the laboratory to the plant, it is necessary to establish a mathematical model of reaction kinetics and mass transfer characteristics to provide a theoretical basis for process scale-up.
While developing the production process, we also need to analyze the environmental impact of the production process, such as solvent emissions, energy consumption, etc., and adopt green chemistry technology.
Finally, process analysis technologies, such as Process Analysis Technologies (PAT), should be applied to achieve real-time monitoring and control of key process parameters.
Technology: Development of nucleic acid formulations using an intelligent delivery platform
Journal: Accounts of Chemical Research
IF: 16.4
Published: 2023
Results:
The authors outline research efforts in developing technology platforms to overcome pharmaceutical bottlenecks in nucleic acid therapeutics. The authors have designed a variety of smart delivery platforms, such as synthetic nanomaterials (i.e., lipid nanoparticles, polymers, and inorganic nanoparticles), physical delivery methods (i.e., electroporation), and naturally derived vectors (i.e., extracellular vesicles), designed to confer nucleic acids with better circulatory stability, targeting affinity, internalization of the cell ("in"), and stimulus-responsive endolysosomal escape ability ("out"). In addition, the authors will discuss progress in developing a range of nucleic acid sequence engineering modification strategies that enhance nuclease resistance, translational efficiency, and potency of nucleic acids while mitigating off-target toxicity and immunogenicity. Integration of these technologies could facilitate the development of nucleic acid therapeutics with robust efficacy and enhanced safety.
Fig. 2 Nucleic acid drug process development. (Lu M, et al., 2023)
With a profound industry background, a comprehensive technology platform, and extensive project experience, CD Formulation can offer customers high-quality services for nucleic acid drug process design and optimization. We can assist customers in successfully launching their products. Contact us, and we will persist in our efforts to contribute to the advancement of the nucleic acid drug industry.
Reference